New trial
Phase 3 64Cu-SAR-bisPSMA PSMA-targeted imaging agent for recurrent prostate cancer
- Trial ID
- NCT06970847 on ClinicalTrials.gov
- Cancer type
- Prostate Cancer
- Stage of research
- Registrational
- Published in
- New in Oncology - July 3, 2025
This study evaluates 64Cu-SAR-bisPSMA PET/CT for detecting prostate cancer recurrence in patients with prior prostatectomy, radiation, cryotherapy, or brachytherapy. Sponsored by Clarity Pharmaceuticals in Omaha, it is a Phase 3 trial assessing a PSMA-directed imaging agent for biochemical recurrence.
More in prostate cancer
-
Trial result · Oct 22, 2026 · NCT03732820
Olaparib (PARP inhibitor) + Abiraterone (CYP17 AR-pathway inhibitor) Extends rPFS in Non‑BRCA mCRPC (PROpel) -
New trial · Oct 15, 2026 · NCT07813637
Phase 1 JANX013 PSMA×CD28 costimulation combines with JANX007 PSMA×CD3 T-cell engagement -
New trial · Oct 15, 2026 · NCT07832292
Phase 2 JNJ-101556143 uses an AR-BRD4 induced-proximity mechanism in resistant prostate cancer -
New trial · Oct 8, 2026 · NCT07824349
Phase 1a/1b JUR-003 KLK2×CD3 bispecific T‑cell engager in metastatic prostate cancer -
New trial · Oct 1, 2026 · NCT07803653
Phase 1 FH-STEAP1 IL-18 CAR T tests STEAP1-targeted CAR-T armored with IL-18